^
Association details:
| Biomarker: | IDH1 mutation |
|---|---|
| Cancer: | Glioma |
| Drug: | BAY1436032 (IDH1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors
Published date:
02/23/2021
Excerpt:
...29 subjects with various tumor types were administered BAY1436032 across 5 doses...lower-grade glioma [LGG]...The best clinical outcomes were in subjects with LGG (n=35), with an objective response rate of 11% (1 CR, 3 PR) and stable disease in 43%. As of August 2020, 4 of these subjects were in treatment for >2 years and still ongoing. Objective responses were observed only in LGG.
DOI:
10.1158/1078-0432.CCR-20-4256
